¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå : Áúȯ À¯Çü, ±â¼ú, Àü¹® ºÐ¾ß, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(2025-2030³â)
Rare Disease Genetic Testing Market by Disease Type (Cancer, Cardiovascular Disorders, Dermatology Diseases), Technology (Array Technology, FISH, Karyotyping), Specialty, End-User - Global Forecast 2025-2030
»óǰÄÚµå : 1601256
¸®¼­Ä¡»ç : 360iResearch Private Limited
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 193 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,939 £Ü 5,699,000
PDF, Excel & 1 Year Online Access (Single User License) help
PDF ¹× Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 4,249 £Ü 6,147,000
PDF, Excel & 1 Year Online Access (2-5 User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿Àϱâ¾÷ ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 5,759 £Ü 8,332,000
PDF, Excel & 1 Year Online Access (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ Áö¿ª »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 6,969 £Ü 10,083,000
PDF, Excel & 1 Year Online Access (Enterprise User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀåÀº 2023³â¿¡ 13¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 15¾ï 4,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 16.15%·Î ¼ºÀåÇϰí, 2030³â¿¡´Â 38¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç´Â Èñ±ÍÁúȯÀÇ ¿øÀÎÀÌ µÇ´Â À¯ÀüÀÚ º¯À̸¦ µ¿Á¤ÇÏ´Â Áø´Ü °Ë»çÀ̸ç, ¸¹Àº °æ¿ì, ¼¼°è¿¡ Èð¾îÁ® ÀÖ´Â ¼Ò¼öÀÇ È¯ÀÚ Áý´Ü¿¡ ¿µÇâÀ» ÁÝ´Ï´Ù. ¸ÂÃãÇü ÀÇ·á, ƯÈ÷ ÀüÅëÀûÀÎ Ä¡·á ¾î·Á¿î °æ¿ì¿¡ °Ü³ÉÇÑ Ä¡·á ¿É¼ÇÀ» Á¦°øÇϴµ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â °Í¿¡ ±âÀÎÇÕ´Ï´Ù. ȯÀÚ »ó´ã, ÀǾàǰ °³¹ß Áö¿ø ±×¸®°í ±× ÃÖÁ¾ ¿ëµµ´Â º´¿ø, Áø´Ü¼¾ÅÍ, ¿¬±¸±â°ü¿¡ À̸¨´Ï´Ù. Á¦¾à ±â¾÷¿¡ ´ëÇÑ ÅõÀÚ ¹× Áø´Ü ´Ü±â ±â¾÷°úÀÇ Á¦ÈÞ°¡ Áõ°¡Çϰí ÀÖ´Â °Íµµ Å« ¼ºÀå ±âȸ°¡ µÇ°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 13¾ï 3,000¸¸ ´Þ·¯
¿¹Ãø³â(2024) 15¾ï 4,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 38¾ï ´Þ·¯
CAGR(%) 16.15%

±×·¯³ª ½ÃÀåÀº °íºñ¿ë, ±ÔÁ¦ °úÁ¦, À¯ÀüÀÚ µ¥ÀÌÅÍÀÇ ÇÁ¶óÀ̹ö½Ã¸¦ µÑ·¯½Ñ À±¸®Àû ¿ì·Á, ½ÅÈï±¹ Áö¿ªÀÇ ³·Àº ÀÎÁöµµ¿Í °°Àº ÇѰ迡 Á÷¸éÇϰí ÀÖ½À´Ï´Ù. °¡°Ý ¼³Á¤, ±ÔÁ¦ ¸íȮȭ ¹× °³ÀÎ Á¤º¸ º¸È£ °­È­°¡ ÇÊ¿äÇÕ´Ï´Ù. ÇÕ¸®ÀûÀÎ °¡°ÝÀÇ ½ÃÄö½Ì ±â¼ú °³¹ß, ¿¹Ãø ºÐ¼®À» À§ÇÑ AI ÅëÇÕ, µ¥ÀÌÅÍ ºÐ¼®À» À§ÇÑ °í±Þ ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º Åø, °³º°È­ µðÁöÅÐ Çコ Ç÷§Æû µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ÁÖ¿ä ±ÇÀå »çÇ×Àº ºÐÀÚÁø´Ü ȸ»ç¿ÍÀÇ Çù·Â °ü°è ÃËÁø, °³±× µ¥ÀÌÅÍ ºÐ¼®ÀÇ È°¿ë, À¯Àü Ä«¿î½½·¯¿Í ȯÀÚÀÇ »óÈ£ÀÛ¿ëÀ» °­È­Çϴ ȯÀÚ Áß½ÉÀÇ ¼Ö·ç¼ÇÀÇ È®¸³ µîÀÌ ÀÖ½À´Ï´Ù. »ý¸í °øÇÐ, µ¥ÀÌÅÍ ºÐ¼® ¹× °Ç°­ °ü¸®ÀÇ À¶ÇÕÀº »õ·Î¿î Ä¡·áÀÔ´Ï´Ù. Ä¡·áÀÇ ±æ°ú Çõ½ÅÀûÀÎ ÄÉ¾î °æ·Î¸¦ âÃâÇÏ´Â »ýŰ踦 ¾à¼ÓÇϰí Èñ±ÍÁúȯ °ü¸®¿¡¼­ ȹ±âÀûÀÎ ±æÀ» ¿­¾î ½ÃÀåÀÇ »óȲÀ» ÆÄ±«ÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. ±â¾÷Àº ÀÌ ÁøÈ­ÇÏ´Â ºÐ¾ß¿¡¼­ ¸®´õ·Î¼­ÀÇ ÁöÀ§¸¦ È®¸³ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ: ±Þ¼ÓÈ÷ ÁøÈ­ÇÏ´Â Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. Á¤¹ÐÈ­ ¹× »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñ ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ À§ÇèÀ» ¿ÏÈ­ÇÒ ¼ö ÀÖÀ¸¸ç, ¶ÇÇÑ ¼ÒºñÀÚ Çൿ ±×¸®°í ±×°ÍÀÌ Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

Porter's Five Forces: Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ´ç½ÅÀº ´õ °­ÀÎÇÑ ½ÃÀå¿¡¼­ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå¿¡¼­ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. È¿°ú¸¦ Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÏ¸é ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡µÇ¾î ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. Æ÷Áö¼Å´× ºÎµå·´°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.ÀÌ ºÐ¼®Àº ½ÃÀå ÁýÁß, ´ÜÆíÈ­ ¹× ÅëÇÕ µ¿ÇâÀ» ¸íÈ®È÷ÇÏ°í º¥´õ´Â °æÀïÀÌ Ä¡¿­ ÇØÁü¿¡ µû¶ó ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÕ´Ï´Ù. Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Á¤º¸¸¦ ±â¹ÝÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. 4°³ÀÇ »çºÐ¸éÀº °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ±¸ºÐÇÏ¿© »ç¿ëÀÚ°¡ Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ½Äº°ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ¾÷°è ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅ͸¦ Æ÷ÇÔÇÑ ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

Á¦6Àå Èñ¼ÒÁúȯ À¯ÀüÀÚ°Ë»ç ½ÃÀå : Áúȯ À¯Çüº°

Á¦7Àå Èñ¼ÒÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå : ±â¼úº°

Á¦8Àå Èñ¼ÒÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå : Àü¹® ºÐ¾ßº°

Á¦9Àå Èñ¼ÒÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ Èñ¼ÒÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Èñ¼ÒÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå

Á¦12Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Èñ¼ÒÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå

Á¦13Àå °æÀï ±¸µµ

±â¾÷ ¸ñ·Ï

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Rare Disease Genetic Testing Market was valued at USD 1.33 billion in 2023, expected to reach USD 1.54 billion in 2024, and is projected to grow at a CAGR of 16.15%, to USD 3.80 billion by 2030.

Rare disease genetic testing involves diagnostic tests to identify gene mutations causing rare disorders, often affecting small patient populations scattered globally. This field's necessity stems from the critical role it plays in early diagnosis, personalized medicine, and providing targeted treatment options, especially when traditional therapies fail. Primarily applied in clinical and research settings, genetic testing supports informed clinical decisions, patient counseling, and drug development, with end-use scope spanning hospitals, diagnostic centers, and research institutes. The growth of genetic testing is driven by advances in genome sequencing technologies, increased awareness, and supportive government policies for rare disease research. Additionally, the increase in pharmaceutical investments and collaborations with diagnostic companies represents significant growth opportunities. A rise in demand for companion diagnostics and precision medicine amplifies market potential, while IT-enabled telehealth solutions ease testing accessibility.

KEY MARKET STATISTICS
Base Year [2023] USD 1.33 billion
Estimated Year [2024] USD 1.54 billion
Forecast Year [2030] USD 3.80 billion
CAGR (%) 16.15%

However, the market faces limitations like high costs, regulatory challenges, ethical concerns around genetic data privacy, and limited awareness in developing regions. These challenges necessitate strategic pricing, clearer regulatory frameworks, and privacy protection advancements to foster market expansion. Innovation hotspots include the development of affordable sequencing technologies, integration of AI for predictive analytics, advanced bioinformatics tools for data interpretation, and personalized digital health platforms. Key recommendations to capitalize on market opportunities include fostering collaborations with molecular diagnostic firms, leveraging big data analytics, and establishing patient-centric solutions that enhance interaction between genetic counselors and patients. The nature of this market is research-intensive and highly specialized, requiring a keen understanding of genomic science and regulatory landscapes. The convergence of biotechnology, data analytics, and healthcare promises a generative ecosystem for novel therapeutic avenues and innovative care pathways, paving the way for breakthroughs in rare disease management and potentially disrupting the market landscape. By navigating regulatory and cost challenges, businesses can position themselves as leaders in this evolving field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Rare Disease Genetic Testing Market

The Rare Disease Genetic Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Porter's Five Forces: A Strategic Tool for Navigating the Rare Disease Genetic Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Rare Disease Genetic Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Rare Disease Genetic Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Rare Disease Genetic Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Rare Disease Genetic Testing Market

A detailed market share analysis in the Rare Disease Genetic Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Rare Disease Genetic Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Rare Disease Genetic Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Rare Disease Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include Laboratory Corporation Of America Holdings, Biora Therapeutics, Inc., 3billion, Inc., Caris Life Sciences, Ambry Genetics Corporation, OPKO Health, Inc., Color Health, Inc., Quest Diagnostics Incorporated, Nonacus Limited, Integrated DNA Technologies, Inc. by Danaher Corporation, Myriad Genetics, Inc., Blueprint Genetics Oy, PerkinElmer Inc., Macrogen, Inc., F. Hoffmann-La Roche Ltd., Variantyx, Inc., Centogene N.V., Fulgent Genetics, Inc., Genomelink, Inc., Illumina, Inc., GeneDx, LLC, Invitae Corporation, Sanofi S.A., Helix OpCo, LLC, Arup Laboratories, The Cooper Companies, Inc., QIAGEN N.V., Realm IDX, Inc., Baylor Genetics, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Rare Disease Genetic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Rare Disease Genetic Testing Market, by Disease Type

7. Rare Disease Genetic Testing Market, by Technology

8. Rare Disease Genetic Testing Market, by Specialty

9. Rare Disease Genetic Testing Market, by End-User

10. Americas Rare Disease Genetic Testing Market

11. Asia-Pacific Rare Disease Genetic Testing Market

12. Europe, Middle East & Africa Rare Disease Genetic Testing Market

13. Competitive Landscape

Companies Mentioned

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â